WHO ICTRP trial
Phase IV-III, open-label, randomized, comparative study, to evaluate the safety…
EUCTR2004-001323-37-ES · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2004-001323-37-ES |
|---|---|
| Public title | Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple therapy on patients infected by HIV that have maintained undetectable HIV viral load during 6 months. OK2004 - OK2004 |
| Scientific title | Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple therapy on patients infected by HIV that have maintained undetectable HIV viral load during 6 months… |
| Primary sponsor | H. 12 de Octubre |
| Secondary sponsors | H. La Paz. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Spain |
| Conditions | Infection by Human inmunideficiency virus |
| Interventions | Trade Name: KALETRA Product Name: Kaletra Soft Capsules Product Code: LPV/r Pharmaceutical Form: Capsule, soft INN or Proposed INN: Lopinavir CAS Number: 192725-17-0 Current Sponsor code: ABT-378 Concentration unit: mg milligram(s)… |
| Registration date | Feb 11, 2004 |
| Secondary IDs | SPA-378-05-40 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: